Clinical trial · Observational
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pleural Mesothelioma | Pleural Mesothelial Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TTFields | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- all patients will receive routine clinical care and TTFields
- interventionNames
- Device: TTFields
Primary outcomes (1)
- measure
- Time from diagnosis of pleural mesothelioma to death of any cause as median overall survival time.
- timeFrame
- 54 Months
Secondary outcomes (2)
- measure
- Number of TTFields treatment-related SAEs, as assessed by the CEC, within total observation period, standardized to average annual incidences.
- timeFrame
- 3 years + 18 months follow up
- measure
- Changes in quality of life comparing baseline with 3 and 6 months after start of TTFields therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥ 18 years of age * Histologically confirmed pleural mesothelioma without any option of curative resection * Planned treatment with NovoTTF-200T System according to IFU and medical guidelines * Life expectancy more than 3 months at day of enrollment * Signed informed consent for use and processing of data Exclusion Criteria: • Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment
References
Publications (0)
Data not yet available